沃森生物(300142.SZ):與玉溪運營公司簽署戰略合作框架協議
格隆匯7月23日丨沃森生物(300142.SZ)公佈,公司於2025年7月22日與玉溪國有資本運營有限公司(簡稱“玉溪運營公司”)簽署了《雲南沃森生物技術股份有限公司與玉溪國有資本運營有限公司的戰略合作框架協議》。基於公司持續發展及業務擴張需求,以及雙方擁有的業務、技術、市場、資本、產業等優勢資源,雙方擬通過資源整合,實現優勢互補,助力產業發展升級,經雙方友好協商,簽署本協議。本協議約定的雙方合作期限暫定為三年,經雙方同意後可展期。
雙方擬圍繞疫苗及生物製品產業領域建立長期、穩定、全面、深入的戰略合作關係,通過充分調動雙方優質產業資源,推動公司在創新疫苗及合成生物製造行業的產業升級和業務擴張發展。雙方將充分發揮各自優勢,在產業資源、產業佈局、產業落地等各方面深化協同。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.